anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Heterotopic ossification (HO), the pathological formation of bone within soft tissues such as tendon and muscle, is a notable complication resulting from severe injury. While soft tissue injury is necessary for HO development, the specific molecular pathology responsible for trauma-induced HO remains a mystery. The previous study detected abnormal autophagy function in the early stages of tendon HO. Nevertheless, it remains to be determined whether autophagy governs the process of HO generation. Here, trauma-induced tendon HO model is used to investigate the relationship between autophagy and tendon calcification. In the early stages of tenotomy, it is observed that autophagic flux is significantly impaired and that blocking autophagic flux promoted the development of more rampant calcification. Moreover, Gt(ROSA)26sor transgenic mouse model experiments disclosed lysosomal acid dysfunction as chief reason behind impaired autophagic flux. Stimulating V-ATPase activity reinstated both lysosomal acid functioning and autophagic flux, thereby reversing tendon HO. This present study demonstrates that autophagy-lysosomal dysfunction triggers HO in the stages of tendon injury, with potential therapeutic targeting implications for HO.
Over a period of 4 weeks, depressive patients will ingest a probiotic food supplementation (Vivomixx®) 4 times a day. Primary and secondary endpoints will be assessed before and after the intervention.
The invention thus pertains to the use of a composition comprising: (a) u ridine or uridine phosphate; and (b) docosahexaenoic acid and/or eicosapenta enoic acid, for improving memory and/or the treatment or prevention of impai red memory function, in a subject with a mini -mental state examination of 2 4-26, wherein said composition is enterally administered to the subject. In the MMSE test, any score of 27 or higher (out of 30) is effectively normal. In the patients with dementia, 20-26 indicates mild dementia, 10-19 moderate dementia, and below 10 severe dementia. It was the present inventors' belie f that within the group of 20 - 26, the memory impairment in the sub-group o f 24 - 26 may even be reversible, as the pathological pathways have just sta rted to develop. In this group of subjects the pathological pathways have ju st started to develop. Clinical studies show excellent results for this subg roup.
Use of tetrahydrofolates in natural stereoisomeric form for production of a pharmaceutical preparation to influence homocysteine levels, to treat and prevent cardiovascular disorders and to prevent neural tube deficiencies is new. The compounds are applied when a methylene tetrahydrofolate reductase deficiency or thermolabile methylene tetrahydrofolate reductase exists. Tetrahydrofolates in the natural (S) form assist remethylation of homocysteine, and therefore act as homocysteine level modulators. They are of use in prevention and treatment of conditions in which there is deficiency of cystathione  beta -synthase and/or 5,10-methylene tetrahydrofolate reductases enzymes. These conditions include cardiovascular disorders, notably arteriosclerosis, and for neural tube deficiencies. The compounds can be used either alone, or in combination with other bioactives, notably vitamins, and especially those of the B-group, B6 and B12, which have synergistic action.
During the follicular phase of the normal menstrual cycle, luteinizing hormone (LH) pulse frequency decreases during sleep. These decreases may be important to support follicle stimulating hormone (FSH) synthesis and secretion. Polycystic ovary syndrome (PCOS) is associated with a persistently rapid gonadotropin hormone-releasing hormone (GnRH) pulse frequency, an abnormality that may account for many of the hormonal manifestations of PCOS. Although one prior study suggests that nocturnal LH frequency decreases slightly in PCOS, methodological issues limit interpretation. Our preliminary data suggest that nocturnal LH frequency does not decrease in untreated PCOS, but that nocturnal decreases of LH frequency are restored with androgen receptor blockade (flutamide) in women with PCOS. We have two hypotheses: (1) Prior to flutamide administration, sleep-associated slowing of LH pulse frequency is less pronounced in women with PCOS compared to that of normally-cycling women in the late follicular phase of the menstrual cycle; (2) After 4 weeks of flutamide administration, sleep-associated LH frequency reduction in women with PCOS is similar to that of normally-cycling women in the late follicular phase of the menstrual cycle. Women with PCOS and normally-cycling women will be studied. For each study participant, LH pulse frequency will be determined (from 1500 to 0700 h) after 4 weeks of flutamide and after 4 weeks of placebo. Flutamide and placebo will be given in random order (i.e., cross-over study). Sleep will be formally evaluated. Flutamide will then be given for 4 weeks prior to reassessment of LH pulse frequency. LH pulse frequency will be analyzed by way of hierarchical mixed effect models. We will use statistical analyses to determine: (a) whether the wake vs. sleep difference in LH frequency is the same for PCOS and normal controls prior to flutamide, and (b) whether the mean wake vs. sleep difference in LH frequency is the same for the two groups after flutamide.
BACKGROUND: Myocardial fibrosis (MF) is a common pathological condition in cardiovascular diseases that often causes severe cardiac dysfunction. MF is characterized by changes in cardiomyocytes, cardiac fibroblasts (CFs), levels of collagen (Col) -1, -3, and overdeposition of the extracellular matrix. Our previous research showed that leonurine (LE) effectively inhibits collagen synthesis and differentiation of CFs, but the mechanism is not fully elucidated. Recent evidence indicates that fat mass and obesity-associated proteins (FTO) regulates the occurrence and development of MF. This study aimed to explore the role of FTO in the antifibrotic effects of LE.
METHODS: Neonatal rat CFs were isolated, and induced using angiotensin II (Ang II) to establish a cell model of MF. Cell viability, wound healing and transwell assays were used to detect cell activity and migration ability. The protein and mRNA levels of MF-related factors were measured following stimulation with Ang II and LE under normal conditions or after FTO knockdown. The RNA methylation level was measured by dot blot assay.
RESULTS: The results showed that LE (20, 40 μM) was not toxic to normal CFs. LE reduced the proliferation, migration and collagen synthesis of Ang II-induced CFs. Further investigation showed that FTO was downregulated by Ang II stimulation, whereas LE reversed this effect. FTO knockdown facilitated the migration of CFs, upregulated the protein levels of Col-3, α-SMA and Col-1 in Ang II and LE-stimulated CFs, and enhanced the fluorescence intensity of α-SMA. Furthermore, LE reduced N6-methyladenosine (m6A) RNA methylation, which was partially blocked by FTO knockdown. FTO knockdown also reduced the expression levels of p53 protein in Ang II and LE-stimulated CFs.
CONCLUSIONS: Our findings suggest that the inhibition of FTO may attenuate the antifibrotic effect of LE in CFs, suggesting that FTO may serve as a key protein for anti-MF of LE.
Patients will be issued Mp3 players and speakers with music files in Mp3 formatted by the randomization team. The intervention arm will be issued the first movement (8 minutes, 22 seconds) of Mozart's Sonata for Two Pianos in D Major, K448. They will be exposed to it once a day during wakefulness for two consecutive months.
Hypoxic-ischemic encephalopathy (HIE) is a devastating condition in which newborn infants are deprived of oxygen in the peripartum period, resulting in brain injury. HIE is a leading cause of infant morbidity and mortality worldwide. Within the last 15 years, the introduction of hypothermia as a therapy for HIE has revolutionized our care of these vulnerable infants, but despite these improvements, nearly 50% of infants die or have major disability at 18 months. Therefore, there is a significant need to develop novel adjunctive therapies for HIE.

Remote ischemic conditioning (RIC) is a procedure that involves the application of brief cycles of non-lethal ischemia and reperfusion to a remote site, with the goal of protecting distant organs exposed to ischemic injury. RIC has been extensively studied in experimental models and applied clinically in adults, children, and neonates. In neonates, there have been trials exploring its potential role before cardiac surgery and necrotizing enterocolitis. Most of these studies performed up to 4 cycles of 5 minutes of ischemia in a single day and found RIC to be feasible and safe. Experimental studies suggest that RIC, acting through three inter-related mechanisms (neural, humoral, and systemic pathways) is associated with increased cerebral blood flow, decreased inflammation, and enhanced cell survival. RIC has been studied as a potential treatment in adult stroke, and while the evidence to date is inconclusive, preliminary data suggest that RIC may reduce the size and the severity of the stroke lesion, as well as improve cognitive outcomes.

RIC has been studied in animal models of perinatal asphyxia and has shown encouraging results. In neonatal rats with HIE, RIC is associated with reduced sensory motor deficits compared to non-RIC, and repeated cycles in three consecutive days is superior to a single treatment. In piglets, four cycles of 10 minutes of bilateral hindlimb ischemia immediately after bilateral common carotid occlusion results in reduced cell death in the periventricular white matter and internal capsule. These preclinical studies support the hypothesis that RIC may be beneficial in infants with HIE. In this proposal, we outline a carefully designed and conducted early phase study of RIC in neonates with HIE.
1,213,348. Coating agents for tablets. BOEHRINGER MANNHEIM G.m.b.H. 26 June, 1968 [28 June, 1967], No. 30475/68. Heading A5B. [Also in Division C3] In a process for the production of a coating agent for orally administrable tablets, said coating agent comprising an aqueous dispersion containing a pharmacologically compatible water-insoluble film-forming synthetic resin, at least one water-soluble non-toxic substance selected from salts, sugars, polyethylene glycols, polyvinyl-pyrrolidones and starch syrups, and/or at least one substance which is soluble in alkaline solutions selected from C 10 -C 20  fatty acids, is first dissolved or suspended in demineralised water, if desired with the use of a small amount of wetting agent, to give a suspension with a viscosity similar to that of the synthetic resin dispersion to be used and this suspension is then slowly mixed with the synthetic resin dispersion, followed by a thorough homogenisation. Edible dyestuffs, pigments and flavourings may also be present. Suitable synthetic resins are polyvinyl esters, acetals, and chlorides, butadiene-styrene co-polymer and polyacrylic acid esters.
If a Heparin resistance appears and the patient meets the inclusion and exclu-sion criteria, he/she will be enrolled. The Heparin administration will be contin-ued and, if necessary increased. Hereby the maximum heparin dose is 1.500 IU per hour.
The invention discloses a traditional Chinese medicine for treating hemorrhoids. The traditional Chinese medicine is prepared according to a traditional Chinese medicine formula referring to clinical practices and treatment experiments, accumulated many years, of the inventor and based on a secret prescription handed down from the ancestors. The traditional Chinese medicine formula for one dose of medicine comprises, by mass, 100g of aristolochia debilis, and is prepared by steps of placing the aristolochia debilis in a decocting apparatus, adding 1500 milliliters of household drinking water, decocting for 20-30 minutes to obtain a decoction, removing dregs of the decoction and cooling until the decoction is warm. A using method of the decoction includes scrubbing the anus twice a day, one in the morning and one in the evening, by 200 milliliters of the decoction each time. The traditional Chinese medicine has a good hemorrhoids treatment effect, a course of treatment includes three days, and the cure rate of one course of treatment is 70% while that of the two courses of treatment is 85%. In addition, the traditional Chinese medicine is easy to prepare, low in cost and particularly suitable for vast rural area.
PURPOSE:To provide the title preventive having the proliferation-inhibitive effect on caries fungi, containing, as active ingredient, a hydrophilic solvent extract from Arecae Semen. CONSTITUTION:Firstly, Arecae Semen is ground and defatted, followed by addition of methanol and carrying out extraction treatment according to a conventional process. Second, the resulting liquid extract is concentrated to dryness followed by extraction with water, and the resultant aqueous solution is mixed with an equal amount of a non-hydrophilic organic solvent to remove organic solvent-solubles. Third, the resulting aqueous layer is put into a dialytic tube 1000 in fractional molecular weight followed by dialysis with water to effect fractionation, and the resultant internal solution is put into a second dialytic tube 10000 in fractional molecular weight followed by dialysis with water to effect fractionation into the internal and external solutions, thus obtaining NF-86 I 1000-10000 in molecular weight and NF-86 II >=10000 in molecular weight both having high caries fungus proliferation-inhibitive activity. Thence, they are each separated and purified using high performance liquid chromatography, resulting the isolation of NF-86IA (molecular weight: 5620). NF-86IB (5000), NF-86IIA (29400), NF-86IIB (8610).
The invention is based on the discovery that STM/Hop promotes proliferation of human glioblastoma-derived cells but not of normal astrocytes and that the proliferation requires the binding of STM/Hop to PrP C . The invention is directed to methods for treating cancer which rely on interfering with the Hop-PrP C  interaction and to peptides, and antibodies raised against the peptides, which directly provide that interference. The invention is further based on the discovery that STI1 230-245  peptide and its human homologue Hop23o-245 provide the desired interference with the STI1/Hop-Pre interaction and inhibit the STI 1/Hop-induced proliferation of glioma and glioblastoma cells. The invention is thus further directed to methods of treating cancer that employ these peptides and functional derivatives thereof, and antibodies directed to the peptides and derivatives. The invention is further directed to means of treating cancer which involve reducing the effective amount of Hop or reducing the expression of Hop. The invention is further directed to means of alleviating or eliminating the side effects of drug therapy and radiotherapy used in treating patients with brain cancers.
PCT No. PCT/AT96/00048 Sec. 371 Date Sep. 17, 1997 Sec. 102(e) Date Sep. 17, 1997 PCT Filed Mar. 14, 1996 PCT Pub. No. WO96/29056 PCT Pub. Date Sep. 26, 1996A topically applicable pharmaceutical composition comprises at least one liquid lipid, at least one pharmaceutical active ingredient which is soluble in at least one of the liquid lipids and is re-absorbed by the skin, and a hydrous gel which is the main component of the composition, whereby at least one lipid and at least one active ingredient are worked into the gel and the composition is essentially free of emulsifying agents and solid constituents, with the exception of the necessary gelatinizing agent required to form the hydrous gel. All of the active ingredients are present in dissolved form, whereby at least one active ingredient is dissolved in the liquid lipid, and this lipid containing the dissolved active ingredient is itself the internal phase and is worked into the hydrous gel as the external phase. The composition is also essentially free of surface-active substances. Process for manufacturing a topically applicable pharmaceutical composition of this kind which provides for the fact that at least one active ingredient re-absorbable by the skin is dissolved, preferably in concentrated form, in a lipid and that this solution is intermingled as the internal phase in a hydrous gel as the external phase, whereby this hydrous gel is the main component in the composition. The composition obtained thereby is highly stable and has favorable galenic properties.
A robber points a gun at a cashier and says: "Only one of these two options is true: If you conceal the combination to the safe, then I kill you; otherwise, if you don´t conceal the combination to the safe, then I kill you." Hearing this statement, most people conclude that, in either case, "I kill you." This is an illusory response, in fact; the valid conclusion states "I don´t kill you." The research reported here studied the roles that different expressions of conditionals ("if-then," "only if," and "if and only if") play in the illusory response. Three experiments show that participants inferred the conclusion "I kill you" from the conditional "if-then" and "I may or may not kill you" from the conditional "only if," while selecting both options with similar frequency for the biconditional "if and only if." These results shed light on the main theories of deductive reasoning.
OBJECTIVE: To explore the clinical characteristics and genetic variant in a child with neurodevelopmental disorders (NDDs).
METHODS: Clinical data of a child who had presented at Xiaogan Hospital Affiliated to Wuhan University of Science and Technology in December 2020 due to intermittent convulsions for over a year were retrospectively analyzed. Peripheral blood samples of the child and his parents were collected and subjected to whole exome sequencing. Candidate variants were verified by Sanger sequencing and bioinformatic analysis. "HNRNPU gene", "epilepsy", "epileptic encephalopathy", "hereditary epilepsy", "neurodevelopmental disorder", "neurodevelopmental syndrome", "HNRNPU", and "NDDs" were used as the key words to search the CNKI, Wanfang and PubMed databases dated from January 1, 1994 to February 10, 2022.
RESULTS: The patient was a 2-year-old boy who had developed seizure at the age of 5 months. His clinical features had included abnormal appearance, recurrent seizures, and low developmental quotients of each functional area as evaluated by the Gesell scale. The child was given sodium valproate for the antiepileptic treatment and rehabilitation training. He had become seizure-free within half a year of follow-up, but his intelligence and motor development did not improve significantly. Genetic testing revealed that he has harbored a heterozygous c.1720_1722delCTT (p.Lys574del) variant of the HNRNPU gene, which was not found in either of his parents. Based on the guidelines from the American College of Medical Genetics and Genomics (ACMG), the variant was rated as likely pathogenic (PS2+PM2_Supporting+PM4). A total of 13 articles were retrieved, and the types of HNRNPU gene mutations have included splice site mutation, nonsense mutation, missense mutation, in-frame deletion, gene duplication, frameshifting mutation, and multiple exon deletion. The main clinical manifestations have included mental retardation, language delay, global developmental delay, epilepsy, craniofacial deformity, mental and behavioral abnormalities.
CONCLUSION: The c.1720_1722delCTT variant of the HNRNPU gene probably underlay the NDDs in this child. Above finding has enriched the mutational spectrum of the HNRNPU gene.
Takotsubo syndrome (TTS) in the pediatric population is an infrequent but relevant cause of morbidity and mortality, with limited studies addressing its clinical course and prognosis. We aimed to analyze the clinical features and prognosis of pediatric TTS in a nation-wide multicenter registry and considering the published literature. We included a total of 54 patients from 4 different hospitals in Spain, as well as pediatric TTS patients from the published literature. Comparisons between groups were performed in order to assess for statistically and clinically relevant prognostic differences between pediatric and adult population features. Patients with pediatric TTS are more commonly male and exhibit a higher prevalence of physical triggers. The left ventricular ejection fraction (LVEF) was significantly lower in the pediatric population (30.5 + 10.4 vs 36.9 + 16.9, p < 0.05), resulting in more than fivefold rates of cardiogenic shock on admission compared to the general adult TTS population (Killip IV 74.1% vs 10.5%, p < 0.001) with similar rates of death and recurrence between groups. TTS in the pediatric population presents a distinctive clinical profile, with higher prevalence of atypical symptoms and physical triggers, as well as higher rates of cardiogenic shock on admission and similar mortality and recurrence rates than those of the adult population. This study provides valuable insights into understanding pediatric TTS and underscores the necessity for further research in this age group.
Antifungal compounds having a benzofuran structure. Antifungals exhibit much less toxicity to human cells than amiodarone. These compounds are useful alone or in combination with other compounds having antifungal activity. Compounds of this invention exhibit synergistic antifungal activity in combination with antifungal amiodarone compounds. The invention provides pharmaceutical compositions useful for treating fungal infections, methods for treating fungal infections and compounds useful in such compositions for treating fungal infections. Compounds of this invention are further useful as antifungal agents for the prevention and or treatment of fungal infections in plants. The invention includes agriculturally useful compositions comprising one or more compounds of this invention which exhibit fungistatic or fungicidal function against one or more plant pathogen is a fungus.
PROBLEM TO BE SOLVED: To easily purify the subject substance useful as e.g. a protein kinase C inhibitor at low cost in high efficiency by extracting K-252a from K-252a- contg. dry microbial cells with a hydrous or anhydrous organic solvent followed by concentration and then recovering the extract. SOLUTION: First, Nocardiopsis sp K-252 (NRRL No.15532) is inoculated into a medium, subjected to shaking culture at 30 deg.C for 3 days to prepare a seed culture fluid, which is then added to a medium packed into a jar fermenter and subjected to submerged culture at 30 deg.C for 7 days, and the resultant culture fluid is put to centrifugal separation to prepare microbial cells, which is then dried to obtain K-252a-contg. dry microbial cells. Thereafter, K-252a is extracted from the dry microbial cells with a hydrous or anhydrous organic solvent so as to come to >=40% in the purity of the K-252a in the liquid extract followed by concentrating the liquid extract and isolating and recovering the extract, thus easily accomplishing the objective highly efficient purification of the aimed K-252a having protein kinase inhibitory activity at low cost.